Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard J. Appleman, Sanjay Thamake, Rodolfo F. Perini, Naseem J. Zojwalla, Eric Jonasch
Topics & Concepts
MedicineErythropoietinClear cell renal cell carcinomaPharmacodynamicsPharmacokineticsRenal cell carcinomaCohortInternal medicineBiomarkerOncologyAdverse effectAnemiaPharmacologyGastroenterologyBiologyBiochemistryCancer, Hypoxia, and MetabolismRenal cell carcinoma treatmentHepatocellular Carcinoma Treatment and Prognosis